Interventional Therapies for Secondary and Essential Hypertension. (Record no. 113874)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11446nam a22005413i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC4644713 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729130644.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2016 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783319341415 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9783319341408 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC4644713 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL4644713 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11247894 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL970063 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)956731144 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC666-701.2 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.13206 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Tsioufis, Costas. |
| 245 10 - TITLE STATEMENT | |
| Title | Interventional Therapies for Secondary and Essential Hypertension. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Cham : |
| Name of producer, publisher, distributor, manufacturer | Springer International Publishing AG, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2016. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2016. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (360 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Updates in Hypertension and Cardiovascular Protection Series |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Foreword -- Preface -- Contents -- Part I: Interventions for Secondary Hypertension -- 1: Interventions for Renovascular Hypertension -- 1.1 Introduction -- 1.2 Indications for Intervention -- 1.3 How Do the Study Results Look Like? -- 1.3.1 Impact of Revascularization on BP Control -- 1.3.2 Impact of Revascularization on Renal Function -- 1.3.3 Impact of Revascularization on Survival -- 1.3.4 Indications for PTRA -- 1.3.5 Contraindications Against PTRA -- 1.4 How to Diagnose a Hemodynamically Significant RAS -- 1.5 Procedural Aspects -- 1.5.1 Techniques and Devices for Endovascular Treatment of RAS -- 1.5.2 Pre- und Postprocedure Medication -- 1.5.3 Access Route -- 1.5.3.1 Femoral Access -- 1.5.3.2 Brachial or Radial Access -- 1.5.4 Preprocedural Angiography -- 1.5.5 Procedure -- 1.5.5.1 Atherosclerotic RAS -- 1.5.5.2 Dedicated Interventional Tools -- 1.5.5.3 Nonatherosclerotic RAS -- 1.5.6 Postprocedural Follow-Up -- 1.5.7 Potential Risks of the Procedure -- 1.5.8 Recommended Equipment Checklist -- 1.6 Patient Follow-Up -- References -- 2: Primary Aldosteronism: A Field on the Move -- 2.1 Introduction -- 2.2 Importance of Detecting Primary Aldosteronism in the Interventional Era -- 2.3 The Magnitude and the Consequences of the Problem -- 2.3.1 Prevalence -- 2.3.2 Cardiovascular Consequences -- 2.4 Diagnosis -- 2.5 Screening -- 2.5.1 Who to Screen -- 2.5.2 Aldosterone to Renin Ratio (ARR) -- 2.5.3 Expert Comment -- 2.6 Confirmation -- 2.6.1 Oral Sodium Load -- 2.6.2 Intravenous Saline Load -- 2.6.3 Fludrocortisone Test -- 2.6.4 Captopril Test -- 2.6.5 Expert Comment -- 2.7 Localization -- 2.7.1 Adrenal Venous Sampling -- 2.7.2 Adrenal Imaging -- 2.7.3 Nuclear Imaging -- 2.7.4 Expert Comment -- 2.8 Management and Follow-Up -- 2.8.1 Adrenalectomy. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.8.2 Mineralocorticoid Receptor Antagonists -- 2.8.3 Adrenalectomy Versus Medical Therapy -- 2.9 Diagnostic and Therapeutic Algorithm -- 2.9.1 Alternative Diagnostic Algorithms -- 2.9.2 Expert Comment -- Conclusion -- References -- 3: Pheochromocytoma/Paragangliomas -- 3.1 Introduction -- 3.2 Clinical Aspects -- 3.3 Diagnosis -- 3.3.1 Laboratory Findings -- 3.3.2 Anatomical Imaging -- 3.3.3 Functional Imaging -- 3.4 Treatment -- 3.4.1 Medical -- 3.4.2 Surgical -- 3.4.3 Palliative Therapy -- 3.5 Follow-Up -- References -- 4: Coarctation of the Aorta -- 4.1 Clinical Presentation and Diagnosis -- 4.2 Indications for Intervention -- 4.3 Therapy -- 4.4 Surgical Treatment -- 4.5 Transcatheter Therapies -- 4.6 Repair of Thoracic Pseudoaneurysms Late After Coarctation Repair -- 4.7 Long-Term Outcomes -- 4.8 Medical Management of Systemic Arterial Hypertension -- 4.9 Surgical Versus Percutaneous Treatment -- 4.10 Follow-Up -- References -- Part II: Adjunctive Therapies -- 5: Sleep Apnea -- 5.1 Introduction -- 5.2 OSAS and BP Levels -- 5.3 Epidemiological Evidence of the Association Between OSAS and Hypertension -- 5.4 Proposed Mechanisms for OSAS-Related Hypertension -- 5.5 Prognostic Relevance of OSAS-Related Hypertension -- 5.6 Diagnostic Approach to OSAS-Related Resistant Hypertension -- 5.7 Effects of Different Therapeutic Strategies on OSAS-Related Resistant Hypertension -- 5.7.1 Effects of Lifestyle Changes and Weight Loss on OSAS-Related Hypertension -- 5.7.2 Effects of CPAP Treatment on OSAS-Related Hypertension -- 5.7.3 Effects of Renal Sympathetic Denervation in OSAS-Related Resistant Hypertension -- 5.8 Do Different Antihypertensive Drug Classes Have Different Effects on OSAS-Related Hypertension? -- Conclusions -- References -- Part III: Interventions for Essential Hypertension. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6: The Impact of Uncontrolled Hypertension on the Cerebrovascular System -- 6.1 Introduction -- 6.2 Blood Pressure Targets in Stroke Prevention -- 6.3 Uncontrolled BP and Cognitive Decline and Dementia -- References -- 7: The Impact of Uncontrolled Hypertension on the Heart -- 7.1 Mechanisms -- 7.2 Detection of Cardiac Damage in Hypertension -- 7.3 Treatment -- 7.4 What Is Uncontrolled Hypertension for Cardiac Complications? -- 7.5 The Issue of BP Target -- Conclusions -- References -- 8: Optimization of Antihypertensive Drug Treatment in Resistant Hypertension -- 8.1 Introduction -- 8.2 Rationalization of the Three Drug Treatment Regimen -- 8.3 Increasing the Dose of the Prescribed Three Drugs -- 8.4 Addition of a Fourth Drug -- 8.5 Mineralocorticoid Receptor Antagonists: Further Evidence -- 8.6 Unmet Needs -- References -- 9: Blood Pressure Measurement Before and After Intervention -- 9.1 Resistant Hypertension -- 9.2 Recommendations at the Evaluation -- 9.2.1 Office BP Measurements -- 9.2.2 Aortic BP -- 9.2.3 Out-of-Office BP -- 9.3 BP After Renal Denervation -- 9.4 Recommendations in the Evaluation -- 9.4.1 Office BP Measurements -- 9.4.2 Aortic BP -- 9.4.3 Out-of-Office BP -- References -- 10: Novel Drugs in the Treatment of Hypertension -- 10.1 Drugs Acting on the Renin-Angiotensin-Aldosterone System -- 10.1.1 Activators of the ACE2/Angiotensin 1-7/Mas Receptor Axis (RAAS Counter-Regulatory System) -- 10.1.2 Anti-Aldosterone Agents -- 10.1.2.1 Aldosterone Synthase Inhibitors -- 10.1.2.2 Mineralocorticoid Receptor Antagonists -- 10.1.3 Centrally Acting Aminopeptidase Inhibitors -- 10.1.4 IRAP Inhibitors (Insulin-Regulated Membrane Aminopeptidase or Insulin-Responsive Aminopeptidase) -- 10.2 Vasopeptidase Inhibitors -- 10.2.1 Dual-Acting Angiotensin Receptor-Neprilysin Inhibitors. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 10.2.2 Dual-Acting Endothelin-Converting Enzyme-Neprilysin Inhibitors -- 10.3 Natriuretic Peptide Receptor Agonists -- 10.4 Vasoactive Intestinal Peptide Receptor Agonist -- 10.5 Drugs Acting on the NO and Soluble Guanylate Cyclase Pathway -- 10.6 Endothelin Receptor Antagonists -- 10.7 Soluble Epoxide Hydrolase Inhibitors -- 10.8 Intestinal Na+/H+ Exchanger 3 Inhibitor -- 10.9 Dopamine β-Hydroxylase (DβH) Inhibitor -- 10.10 Vaccines -- 10.11 Drugs for Treatment of Preeclampsia -- 10.12 Outlook: Novel Targets and Drugs Delivered from Genomics and Pharmacogenomics -- References -- 11: Adherence to Medications in Uncontrolled Hypertension -- 11.1 Introduction -- 11.2 Defining Adherence and Its Various Components -- 11.3 Clinical Assessment of Drug Adherence: A Major Challenge -- 11.4 Adherence in Hypertension -- 11.5 When Should Adherence Be Monitored in Hypertension? -- 11.6 How to Improve Drug Adherence in Uncontrolled Hypertension? -- Conclusions -- References -- 12: Pathophysiology of Renal Sympathetic Denervation (RSDN) -- 12.1 Introduction -- 12.2 What Types of Nerves Are Linking the Kidney to the Brain? -- 12.2.1 Renal Efferent Sympathetic Nerves -- 12.2.2 Renal Afferent Sympathetic Nerves -- 12.3 Effects of Kidney Nerves: Stimulation or Denervation? -- 12.4 Kidney-Nerve Interaction: Role of Denervation in Hypertension -- 12.5 Perspective-Conclusion -- References -- 13: Renal Denervation: A Historical Perspective -- 13.1 Introduction -- 13.2 Historical Perspective -- 13.2.1 Animal Models -- 13.3 Renal Denervation in Humans -- 13.4 Catheter-Based Renal Denervation -- Conclusion -- References -- 14: Procedural Aspects of Renal Sympathetic Denervation -- 14.1 Introduction -- 14.2 Optimal Sites for RDN -- 14.2.1 Renal Vascular Characteristics -- 14.2.2 Locating Sympathetic Nerves. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 14.2.3 Lesion Sites for Increased Efficacy -- 14.3 Modalities and Systems for RDN -- 14.3.1 Radiofrequency Ablation -- 14.3.2 Ultrasound Ablation -- 14.3.3 Chemical Ablation -- 14.4 Prior to Procedure -- 14.4.1 Confirming Resistant Hypertension -- 14.4.2 Kidney Function -- 14.4.3 Age, Comorbidities, and Special Conditions -- 14.4.4 Imaging -- 14.4.5 Prevention of Contrast Nephropathy -- 14.5 Renal Denervation -- 14.5.1 Patient Preparation -- 14.5.2 Periprocedural Medication -- 14.5.3 Angiography -- 14.5.4 Renal Denervation Procedure -- 14.5.5 System-Specific Steps -- 14.5.5.1 Single-Electrode Systems -- 14.5.5.2 Multielectrode Systems -- 14.5.5.3 The Paradise® Ultrasound System -- 14.5.5.4 Concluding RDN -- 14.6 Follow-Up -- 14.7 Centers for Renal Denervation -- 14.8 Renal Nerve Stimulation -- Conclusion -- References -- 15: Safety of Renal Denervation -- 15.1 Introduction -- 15.2 An Overview of Preclinical and Laboratory Data -- 15.3 Safety Data from Principal Trials -- 15.3.1 The Symplicity HTN-1 and HTN-2 Studies -- 15.3.2 The Symplicity HTN-3 Study -- 15.3.3 The EnligHTN I Study -- 15.3.4 The RAPID Study -- 15.3.5 The REDUCE-HTN Study -- 15.4 Safety Data from Registries and Meta-analyses -- 15.5 Special Issues -- 15.5.1 Autonomic Dysfunction -- 15.5.2 Renal Artery Stenosis -- 15.5.3 Kidney Function -- References -- 16: Efficacy of Renal Denervation on Blood Pressure Reduction -- 16.1 Introduction -- 16.2 Preclinical Data -- 16.3 Proof-of-Concept Studies -- 16.4 Randomized Controlled Studies -- 16.5 Registries: Real-World Data -- 16.6 Randomized Sham-Controlled Studies -- 16.6.1 Symplicity HTN-3 Trial -- 16.7 Controversial BP Reduction Post RDN: Possible Explanations -- 16.7.1 Incomplete Renal Denervation in Many Patients -- 16.7.2 Medication Stability and Adherence. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 16.7.3 Appropriate Hypertensive Population for RDN: Identification of Responders Post RDN. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Heart_xSurgery. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Schmieder, Roland E. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mancia, Giuseppe. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Tsioufis, Costas |
| Title | Interventional Therapies for Secondary and Essential Hypertension |
| Place, publisher, and date of publication | Cham : Springer International Publishing AG,c2016 |
| International Standard Book Number | 9783319341408 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Updates in Hypertension and Cardiovascular Protection Series |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4644713">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4644713</a> |
| Public note | Click to View |
No items available.